Competition for Novo Nordisk’s (NOV: N) recently-approved weight loss drug Wegovy (semaglutide) is coming quickly, with Eli Lilly (NYSE: LLY) securing Fast Track designation for its rival therapy.
Marketed in diabetes as Mounjaro, tirzepatide is being developed as an option for adults with obesity, or overweight with weight-related comorbidities.
Based on its discussions with the US regulator, Lilly said it plans to initiate a rolling submission of a new drug application (NDA) later this year, based primarily on results from the Phase III SURMOUNT-1 and SURMOUNT-2 trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze